Role in Portfolio Management Meetings

R&D organizations with larger portfolios are likely to run routine portfolio management meetings to a) track progress on project progress, b) approve or validate milestone decisions on projects, and start and terminate projects.  The large pharma have sufficiently large therapy area portfolios that each TA may run its own portfolio management meeting and split such meetings by Discovery, early Development and Late Development.  Portfolio managers are well suited to manage such meetings due to their neutral position in the matrix and their interest in ensuring prompt equitable decisions on project milestone progression.